Premium
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following...
Communiqué de presse : Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO Dupixent est le premier médicament biologique approuvé aux États-Unis...
Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled...
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent approved in the US as the first-ever biologic medicine for patients with...
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations...
Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on...
Communiqué de presse : Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la...
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval...
Press Release: Availability of the Q3 2024 Aide mémoire Availability of the Q3 2024 Aide mémoire Paris, France – September 26, 2024. Sanofi announced today that its Q3 2024 Aide mémoire is...
Availability of the Q3 2024 Aide mémoire Paris, France – September 26, 2024. Sanofi announced today that its Q3 2024 Aide mémoire is available on the "Investors" page of the company's website:...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.1 | -0.0982125319191 | 101.82 | 104.46 | 99.87 | 1579257 | 102.55555711 | DE |
| 4 | -2.66 | -2.54838091588 | 104.38 | 106.08 | 99.87 | 1588529 | 103.37371511 | DE |
| 12 | 7.25 | 7.67439398751 | 94.47 | 106.14 | 90.73 | 1452055 | 99.61514113 | DE |
| 26 | 12.91 | 14.536651278 | 88.81 | 106.14 | 85.07 | 1477274 | 94.24719016 | DE |
| 52 | -0.2 | -0.196232339089 | 101.92 | 106.14 | 80.6 | 1494037 | 91.84854933 | DE |
| 156 | 18.12 | 21.6746411483 | 83.6 | 106.66 | 76.45 | 1772292 | 92.11570567 | DE |
| 260 | 20.55 | 25.3172354318 | 81.17 | 106.66 | 67.65 | 1968133 | 88.97024844 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
103
